Clinical Trial Update: CONVERGE Post-Approval Study (PAS) [NA]

View source ↗

Summary

AtriCure's CONVERGE Post-Approval Study (PAS) for chronic atrial fibrillation remains active but not recruiting, according to the registry update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: AtriCure, Inc. | Conditions: Chronic Atrial Fibrillation | NA | Status: ACTIVE_NOT_RECRUITING